Heart failure (HF) represents a global pandemic health problem with a high impact on health-
care costs, affecting about 26 million adults worldwide. The overall HF prevalence and …

At least one-half of the growing heart failure population consists of heart failure with
preserved ejection fraction (HFpEF). The limited therapeutic options, the complexity of the …

Aims More than 50% of patients with heart failure have preserved ejection fraction
characterized by diastolic dysfunction. The prevalance of diastolic dysfunction is higher in …

Aims The association between heart failure and dementia remains unclear. We assessed
the risk of dementia among patients with heart failure and members of a general population …

Background: Clinical utility of cardiac biomarker testing during pregnancy in women with
preexisting cardiac disease is not well known. We studied the levels and temporal trends of …

Background In patients with heart failure (HF), randomized controlled trials (RCTs) of sodium-
glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in decreasing the …

Aims Many studies show the association between malnutrition and poor prognosis in heart
failure (HF) patients. Our research aimed to analyse sex differences in patients with HF with …

Background and Objectives: There is emerging evidence of the usefulness of left atrial strain
(LAS) in the assessment of diastolic dysfunction (DD). In this study we assess the sensitivity …

Heart failure with preserved ejection fraction (HFpEF) is a major unmet medical need that is
characterized by the presence of multiple cardiovascular and non-cardiovascular …

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown
to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF) …